Immunotherapy side effects under the microscope: new study monitors autoantibodies

NCT ID NCT04220034

Completed Knowledge-focused Sponsor: CHU de Reims Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies linked to autoimmune diseases. The goal was to better understand and potentially predict autoimmune side effects from these powerful cancer drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors predict and manage autoimmune side effects in cancer patients receiving checkpoint inhibitors.
What could go wrong: This is an observational study, not a treatment trial. It only measures antibody levels and does not test any new therapy or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ADVERSE EFFECTS OF ANTI-NEOPLASIC DRUG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplastic disease or syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE ADVERSE EFFECTS OF ANTI-NEOPLASIC DRUG

Contacts and locations

Locations

Chu Reims

Reims, 51092, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.